Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Gains from Investment Securities (2016 - 2025)

Sutro Biopharma (STRO) has disclosed Gains from Investment Securities for 10 consecutive years, with -$111000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 109.92% to -$111000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 51.72% year-over-year, with the annual reading at $359725.0 for FY2025, 3041.98% up from the prior year.
  • Gains from Investment Securities hit -$111000.0 in Q4 2025 for Sutro Biopharma, down from $29069.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.9 million in Q1 2021 to a low of -$463000.0 in Q4 2022.
  • Historically, Gains from Investment Securities has averaged $172027.9 across 5 years, with a median of $13000.0 in 2023.
  • Biggest five-year swings in Gains from Investment Securities: crashed 190.96% in 2022 and later soared 640.37% in 2025.
  • Year by year, Gains from Investment Securities stood at $509000.0 in 2021, then crashed by 190.96% to -$463000.0 in 2022, then skyrocketed by 101.64% to $7606.0 in 2023, then surged by 14612.07% to $1.1 million in 2024, then crashed by 109.92% to -$111000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for STRO at -$111000.0 in Q4 2025, $29069.0 in Q3 2025, and $62739.0 in Q2 2025.